Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-06-28
2005-06-28
Shah, Mukund J. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S016000, C546S018000, C544S182000, C544S231000
Reexamination Certificate
active
06911452
ABSTRACT:
The present invention relates to 1-oxa-3,8-diaza-spiro[4.5]decan-2-one compounds as monoamine receptor modulators; compositions comprising the same; methods of inhibiting an activity of a monoamine receptor with said compounds; methods of treating a disease condition associated with a monoamine receptor using said compounds; and methods for identifying a subject suitable for treatment using said compounds.
REFERENCES:
patent: 4255432 (1981-03-01), Kluge et al.
patent: 4353900 (1982-10-01), Clark
patent: 4853394 (1989-08-01), King et al.
patent: 5707798 (1998-01-01), Brann
patent: 6107324 (2000-08-01), Behan et al.
patent: 6140509 (2000-10-01), Behan et al.
patent: 6150393 (2000-11-01), Behan et al.
patent: 6358698 (2002-03-01), Weiner et al.
patent: 0061333 (1982-09-01), None
patent: WO 97/11940 (1997-04-01), None
patent: WO 99/52927 (1999-10-01), None
patent: WO 01/66521 (2001-09-01), None
Bhatia, et al., 5-Lipoxygenase inhibitors: synthesis and structure-activity relationships of a series of 1-Aryl-2H,4H-tetrahydro-1,2,4-triazin-3-ones, J. Med. Chem. 39:3938-3950 (1996).
Barchas, et al., Serotonin and Behavior (1973), (contents only, 4 pages).
Barnes & Sharp, A review of central 5-HT receptors and their function, Neuropharmacology, 38:1083-1152 (1999).
Barr & Manning, Agonist-independent activation of Gzby the 5-hydroxytryptamine1Areceptor co-expressed inspodoptera frugiperdacells, J. Biol. Chem. 272:32979-87 (1997).
Bassus et al., Psychotropes potentials. X. Synthese de butyrophenones a cycle piperidine-spiro-tetrahydrooxazinone douees d'activite neuroleptique, Eur. J. Med. Chem.—Chim. Ther. 9:416-423 (1974).
Bond et al., Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the β2-adrenoceptor, Nature 374:272 (1995).
Boullin, Serotonin In Mental Abnormalities 1:316 (1978).
Caroon et al., Synthesis and antihypertensive activity of a series of 8-substituted 1-oxa-3,8-diazaspiro[4.5]decan-2-ones, J. Med. Chem. 24:1320-1328 (1981).
Cerione et al., The mammalian β2-adrenergic receptor: reconstitution of functional interactions between pure receptor and pure stimlatory nucleotide binding protein of the adenylate cyclase system, Biochemistry 23:4519-25 (1984).
Brann, Identification of ligands by selective amplification of cells transfected with receptors and marker enzymes, Chem. Abstr. 128:111548 (1998).
Clark et al., Antihypertensive 9-substituted 1-Oxa-4,9-diazaspiro[5.5]undecan-3-ones, J. Med. Chem. 26:855-861 (1983).
Fisera et al., Synthesis of spiro-substituted 1,3-oxazines by a new sequence leading to spiroheterocycles, Monatsh. Chem. 125:909-919 (1994).
Fuller, Drugs acting on serotonergic neuronal systems, Biology of Serotonergic Transmission, chapter 9, 221-247 (1982).
Gawley and Aubé, Pergamon, 1996, ISBN 0 08 0418759.
Gershon, et al., 5-Hydroxytryptamine and enteric neurones, in the Peripheral Actions of 5-Hydroxytryptamine, Oxford University Press, 247-273 (1989).
Glennon, Serotonin receptors: clinical implications, Neurosci. Biobehavioral Rev. 14:35-47 (1990).
Gstach et al., Rearrangement of 3,3-disubstituted 1-Aryl-4,5-dihydro-5-oxo-3H-1,2,4-triazolium Tetrafluoroborates; Part 1. A versatile synthesis of 1,5-disubstituted 2-Aryl-1,2-dihydro-3H-1,2,4-triazol-3-one Tetrafluoroborates, Synthesis 803-808 (1990).
Mavunkel et al., Synthesis and characterization of pseudopeptide bradykinin B2 receptor antagonists containing the 1,3,8-triazaspiro[4.5]decan-4-one Ring System, J. Med. Chem. 39:3169-3173 (1996).
Meltzer, The role of serotonin in antiphsycotic drug action, Neuropsychopharmacology, 21:106S-115S (1999).
Meng et al., Synthetic approaches toward glidobamine, the core structure of the glibobactin antibiotics, Tetrahedron 47:62510-6264 (1991).
Moulignier, Recepteurs centraux de la serotonine principaux aspects fondamentaux et fonctionnels application therapeutiques, Rev. Neurol. 150:3-15, (1994).
Mullen et al., (-)-Spiro[1-azabicyclo[2.2.2]octane-3,5′-oxazolidin-2′one], a conformationally restricted analogue of acetylcholine, is a highly selective full agonist at the α7 nicotinic acetylcholine receptor, J. Med. Chem. 43:4045-4050 (2000).
Saltzman et al., Cloning of the human serotonin 5-HT2 and 5HT1C receptor subtypes, Biochem. Biophys. Res. Comm. 181:1469-78 (1991).
Saxena, et al., Cardiovascular effects of serotonin agonists and antagonists, J. Cardiovascular Pharmacol. 15(Supp. 7):S17-S34 (1990).
Smith et al., New spiropiperdines as potent and selective non-peptide tachykinin NK2receptor antagonists, J. Med. Chem. 38:3772-3779 (1995).
Tsukamoto et al., Synthesis and structure-activity studies of a series of 1-oxa-2,8-diazaspiro[4.5]decan-3-ones and related compounds as M1muscarinic agonists, Chem. Pharm. Bull. 43(9):1523-1529 (1995).
Wiener et al., 5-Hydroxytryptamine2Areceptor inverse agonists as antipsychotics, J. Pharmacol. Exp. Ther. 299(1):268-276 (2001).
International Search Report (PCT/US02/41476), date of mailing: Aug. 5, 2003.
Acadia Pharmaceuticals Inc.
Habte Kahsay
Shah Mukund J.
LandOfFree
Spiroazacyclic compounds as monoamine receptor modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Spiroazacyclic compounds as monoamine receptor modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Spiroazacyclic compounds as monoamine receptor modulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3479379